* If you want to update the article please login/register
3 Small cell lung cancer, 2 Gastric/esophageal adenocarcinoma, 3 Castration-resistant prostate adenocarcinoma, 4 Soft tissue sarcoma, 5 Ovarian adenocarcinoma, 5 Advanced well-differentiated neuroendocrine tumors, and 7 Diffuse large B cell lymphoma DLBCL" were among the 7 tumor cohorts evaluated, including 1 Small cell lung cancer, 2 Small cell s Participants underwent study treatment for up to two years or until disease progression was determined by an investigator, or until studier's approval of study completion was withdrawn. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT03365791
"This is a sample acquisition protocol for the targeted study of hematologic malignancies by a network of NIH investigators from various Institutes/Centers. " Objective: This biology method is intended to enable sample collection for use in the analysis of hematologic malignancies. Eligibility: Diagnosis of any acute lymphoblastemia or pre-malignant diseases, including but not limited to the following: Acute Lymphoma, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin s Lymphoma, Non-Hodgkin's Disease Tumor : The following: Myeligibility of any acute Mye ste Mye e Mye tys Mye t Mye Myemo Mye Brux Mye My The study of hematologic malignancies will be carried out in an exploratory manner, while some studies are of a developmental type, i. e. , assay design for ongoing or planned CC clinical trials. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT00923442
"The primary aim of this IRB study is to perform immune profiling focusing on the detection of MDSCs over time in patients receiving CAR T therapy and determining the correlation between immune profile and disease relapse/resistance in CAR T therapy. " All hematologic malignancy patients treated with commercial CAR T products will be tested and accepted for the study. At one year after CAR T care, overall survival, or progression-free survival, the investigators will perform multivariable regression to see if the number and function of MDSCs can be used as independent predictors of disease relapse.
Source link: https://clinicaltrials.gov/ct2/show/NCT05397132
Busulfan dosing will be as follows: patients 12 kg: 1. 1 mg/kg/dose IV every 6 hours for 16 doses; patients 12 kg: 0. 8 mg/kg/dose IV every 6 hours for 16 doses; patients > 12 kg: 1. 1 mg/kg/dose IV every 6 hours for 16 doses total; patients > 12 kg: 0. 8 mg/kg/dose IV every 6 hours for 16 doses. FLUDARABINE: Fludarabine is a drug that is administered in a single hour for three days. CSA will be converted to an oral form as soon as the patient tolerates oral medications and has a normal gastrointestinal transit time. MMF will begin on Day 0 with a dose of 15 mg/Kg IV or orally TID, and will be discontinued on Day +45 unless GVHD is present. Patients with CNS relapse or primary CNS disease that is symptomatic or related to radiological disorders will receive additional radiation to the craniospinal axis of the CNS. SUPPORTIVE CARE: The Texas Children's Hospital's Blood and Marrow Cell Transplant program will include all prophylactic and therapeutic clinical care issues. IVIG: Intravenous immunoglobulin will be given monthly until discontinuation of GVHD therapy and documentation of antibody production are discontinued. Patients enrolled in CB-CTLs may also be eligible for infusion of CB-derived multivirus-specific CTL to provide virus-specific immune reconstitution and treatment of viral infections after CBT can be included in the CB-CTL regimen. Following on the BMT clinics on a regular basis as indicated by the primary physician after being hospitalized.
Source link: https://clinicaltrials.gov/ct2/show/NCT01247701
"""" """ says the signer.
Source link: https://clinicaltrials.gov/ct2/show/NCT03248479
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions